HU | EUR
Logged in as::
HU | EUR
You are about to leave this site.
Please be aware that your current cart is not saved yet and cannot be restored on the new site nor when you come back. If you want to save your cart please login in into your account.
Liquid Biopsy: Novel Methods May Ease Cancer Detection and Therapy
Explore Life Science
Breakthrough in individualized cancer treatment? US scientists are working on new methods to detect cancer in blood samples. The so-called liquid biopsy method is a promising alternative for individualized cancer diagnosis and therapy monitoring.
In industrialized countries, every third person will develop cancer in their lifetime. Cancer is the second most common cause of death in these countries, which has made it one of the key healthcare issues for decades. Scientists and medical experts around the globe are busy conducting research into new medicines and advanced methods for cancer detection and treatment, a challenging field of science. Because each instance of cancer is unique, it's not a clearly-definable disease. Cancer tumor cells are different and even the cells of a single cancer type exhibit individual characteristics. Liquid biopsy is a promising technique to set against the diverse physiological characteristics of cancer diseases.
Single blood draw for cancer testingTraditional biopsy methods are currently the most common way to detect cancer. However, taking the tissue samples requires invasive surgery, which is not always possible to perform. Sometimes such an intervention is too exhausting for a weak patient, or the tumor is located in an unreachable part of the body. In contrast, liquid biopsy only needs a blood sample, making it much easier to carry out. In its original form, liquid biopsy is based on a determination of tumor markers from the blood. These markers are proteins that can be detected in high concentrations in certain tumor diseases. Nowadays, even malignant cells emitted into the blood stream by a tumor, and cell-free DNA scattered into the blood by dying tumor cells, can be detected.
As good as the conventional wayA recent study presented at this year’s annual meeting of the American Society of Clinical Oncology demonstrates that blood tests can be an adequate non-invasive alternative to tissue biopsy. In the large-scale genomic analysis, blood samples from more than 15,000 patients and 50 different tumor types were analyzed. It was one of the largest cancer studies ever conducted. Scientists at the University of California Comprehensive Davis Cancer Center in Sacramento, California observed that the mutation patterns in circulating tumor DNA in blood samples mirror those which are identified in traditional tumor tissue biopsy.
A promising alternativeAnother team of scientists at the University of Washington in Seattle pursued another strategy and published their study early this year in Cell, a scientific journal. They also analyzed cell-free tumor DNA from the blood, but were not looking for mutations as described above. Instead, their novel liquid biopsy method is based on DNA packaging structures, identifying what types of cells gave rise to the cell-free DNA. In a living cell, the DNA is folded around protein cores that build up structures called nucleosomes. Every cell has a slightly different way to pack its DNA. When a cell dies, its DNA is divided between the nucleosomes and then spread out to the blood. The resulting nucleosome patterns are specific to every single cell type. This phenomenon is the basis for the new approach, which analyzes the nucleosome footprint of cell-free DNA. In healthy humans, the scientists mainly found DNA from lymph nodes and bone marrow, tissues with high cell production and death rates. The nucleosome footprint is unique in cancer patients. It can reveal the origin of the primary tumor, which is currently not found in five percent of all cancer diseases.
Vital hopesThe clinical implementation of liquid biopsy is not yet widespread. However, this novel method may revolutionize cancer diagnostics and therapy. It can improve monitoring the progression of the disease, the response to therapy and the development of treatment resistances. It allows personalized therapies and eases screening procedures.